Galactomannan testing during mold-active prophylaxis.
作者信息
Cornely Oliver A
机构信息
Department I of Internal Medicine, Clinical Trials Centre Cologne, Center for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Germany.
出版信息
Clin Infect Dis. 2014 Dec 15;59(12):1703-4. doi: 10.1093/cid/ciu677. Epub 2014 Aug 27.
Abstract
摘要
相似文献
1
Galactomannan testing during mold-active prophylaxis.
Clin Infect Dis. 2014 Dec 15;59(12):1703-4. doi: 10.1093/cid/ciu677. Epub 2014 Aug 27.
2
Serum galactomannan diagnosis of breakthrough invasive fungal disease.
Clin Infect Dis. 2015 Apr 15;60(8):1284. doi: 10.1093/cid/civ035. Epub 2015 Jan 26.
3
Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis.
Clin Infect Dis. 2014 Dec 15;59(12):1696-702. doi: 10.1093/cid/ciu673. Epub 2014 Aug 27.
4
Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis.
Med Mycol. 2017 Jul 1;55(5):528-534. doi: 10.1093/mmy/myw102.
5
Timing of broncho-alveolar lavage for galactomannan testing in hematological oncology patients.
Clin Respir J. 2017 Jul;11(4):534-536. doi: 10.1111/crj.12380. Epub 2015 Oct 2.
6
Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.
J Infect Dis. 1994 Feb;169(2):356-68. doi: 10.1093/infdis/169.2.356.
7
Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients.
Exp Clin Transplant. 2012 Jun;10(3):278-81. doi: 10.6002/ect.2011.0176.
8
Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care.
Expert Rev Mol Diagn. 2018 Jul;18(7):601-604. doi: 10.1080/14737159.2018.1488589. Epub 2018 Jun 20.
9
Reply to Lewis et al.
Clin Infect Dis. 2015 Apr 15;60(8):1285. doi: 10.1093/cid/civ036. Epub 2015 Jan 26.
10
[Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis].
Rev Iberoam Micol. 2003 Sep;20(3):103-10.
引用本文的文献
1
Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience.
J Med Microbiol. 2022 Jul;71(7). doi: 10.1099/jmm.0.001564.
2
Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis.
J Fungi (Basel). 2021 May 26;7(6):417. doi: 10.3390/jof7060417.
3
Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study.
Bone Marrow Transplant. 2017 Feb;52(2):326-329. doi: 10.1038/bmt.2016.279. Epub 2016 Oct 31.
4
Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies.
J Clin Microbiol. 2016 Mar;54(3):771-4. doi: 10.1128/JCM.02969-15. Epub 2015 Dec 23.
本文引用的文献
1
As galactomannan disappoints, our quest for a feasible diagnostic standard for invasive aspergillosis continues.
Am J Respir Crit Care Med. 2014 Aug 1;190(3):248-9. doi: 10.1164/rccm.201407-1227ED.
2
Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease.
Am J Respir Crit Care Med. 2014 Aug 1;190(3):309-17. doi: 10.1164/rccm.201403-0431OC.
3
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.
Clin Microbiol Infect. 2014 Apr;20 Suppl 3:5-26. doi: 10.1111/1469-0691.12371.
4
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4.
5
Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO).
Ann Oncol. 2012 Apr;23(4):823-33. doi: 10.1093/annonc/mdr407. Epub 2011 Sep 23.
6
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
J Antimicrob Chemother. 2010 Jul;65(7):1466-71. doi: 10.1093/jac/dkq121. Epub 2010 Apr 21.
7
Galactomannan detection and diagnosis of invasive aspergillosis.
Clin Infect Dis. 2010 Apr 1;50(7):1070-1; author reply 1071-2. doi: 10.1086/651161.
8
Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases.
Clin Infect Dis. 2009 Dec 1;49(11):1688-93. doi: 10.1086/647935.
9
Posaconazole-increased vincristine neurotoxicity in a child: a case report.
J Pediatr Hematol Oncol. 2009 Apr;31(4):292-5. doi: 10.1097/MPH.0b013e31819b9d01.
10
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094.
Zotero 插件